←
Evaluate Pharma7,656 posts
Evaluate Pharma avatar

Evaluate Pharma

@evaluatepharma

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.

◷ Joined June 2009▧ 3,555 Photos and videos
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·6h

"I consider myself an expert; I’ve been doing this for decades and can now do it in 10 minutes." – a Business Development Strategist at a global med-tech company on Atlas CI from @NorstellaCo, an AI agent for competitive intelligence. Learn more: vist.ly/5tbw2

0:05
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·7h

Tomorrow at 3pm GMT, 10am ET, join our experts for How Good Is Your AI Answer? Scoring Agents on Real Pharma Questions. Learn the four parts of an AI agent and how to test an AI product with expert-written answers. Register now: vist.ly/5tbm7

0:07
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·10h

Many forecasters build in Excel, then copy results into an online tool, and the calculations behind the numbers disappear. Andrew Ward explains why a good forecast lets you dig into the drivers. FC+ keeps everything in Excel, where your team can see it. vist.ly/5tayc.

2:20
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 17

Atlas BD&L is coming to Norstella Atlas: an AI agent that takes BD&L teams from target list to defensible investment case. Scout, run diligence, and benchmark deals, built on Norstella’s proprietary data with sources attached. Learn more: vist.ly/5t7je

0:05
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 17

Last chance to register. Tomorrow, Evaluate and @alvarezmarsal host a virtual fireside chat on biotech IPO and M&A readiness. Brian Bock opens with Evaluate data, followed by a panel moderated by Eduardo Schur. Register now to join us live: vist.ly/5t7d8

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 17

Evaluate Spotlight Ep. 06: Metabolic is now live! Obesity grew by more than 50% a year between 2019 and 2026 and is forecast to lead every therapy area again by 2033. Watch Mark Lansdell and Jack Hughes discuss what's driving the market. vist.ly/5t63v

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 17

Without strategic alignment, the Annual Operating Plan (AOP) becomes just a wish list. Teams must first agree on 3-5 key objectives. Check out our report with J+D Forecasting for best practices: vist.ly/5t57n

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 16

95% of senior pharma executives say their companies use AI, but only 9% call its impact on commercial decisions transformational. Learn how to evaluate AI products on real pharma questions. November 19 | 3pm GMT / 10am ET Register: vist.ly/5szh9

0:07
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 16

Oncology data reveals critical trends: 150+ acquisitions analyzed; ADCs and bispecifics rose from 10% in 2020 to a third today; only half of top companies show growth through 2032; US funding cuts risk early-stage pipelines. ▶️ Watch the full episode: vist.ly/5syxf

Post attachmentPost attachmentPost attachmentPost attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 16

From the first phase of development through to loss of exclusivity, forecasting needs to adapt as the product, the team, and the stakes change. Andrew Ward covers how in this short video. Learn more about J+D Forecasting solutions: vist.ly/5sxt2

2:20
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 16

Patent cliffs, pipeline gaps, and China’s growing biotech influence are reshaping pharma M&A. Six companies have spent $120B+ on deals since 2024. See what’s next in the Evaluate World Preview 2026. Download it here: vist.ly/5sxsw

0:16
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 15

Want to stay on top of the key trends and insights in biopharma in 2026? Sign up for our monthly Evaluate Discovery newsletter to get the latest thought leadership and analysis from our experts: vist.ly/5svkd

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 15

Oncology dealmaking is evolving! The mega-merger era is fading, replaced by a targeted M&A approach. In Ep. 02 of Evaluate Spotlight, Ethan Smith and Sofia Petta discuss the implications for pipelines and financing. ▶️ Watch now: vist.ly/5su2x

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 14

Most AOP processes falter due to siloed planning, reliance on flawed prior-year data, or skipping market briefs. These issues are fixable! Discover effective AOP practices in our report with J+D Forecasting. Download it here: vist.ly/5ssuy

Post attachmentPost attachmentPost attachmentPost attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 14

Have you registered for the new Evaluate Discovery newsletter yet? Don't miss out on our most-read content delivered straight to your inbox. Sign up to receive the Evaluate Discovery newsletter now! ✉️✨ vist.ly/5ssd6

Post attachment
Evaluate Pharma avatar
Evaluate Pharma@evaluatepharma·Nov 13

Market data helps biotech leaders decide when and how to move. On Nov. 18 at noon ET, Evaluate’s Brian Bock shares data to open an @alvarezmarsal fireside chat on IPO and M&A readiness, moderated by Eduardo Schur. Register to hear the panel’s take: vist.ly/5snkk

Post attachment